HEDIS Measure: Statin Use in Patients with Cardiovascular Disease (SPC)

We are committed to working with you to improve the quality of care and health outcomes for our members, your patients. HEDIS® (Healthcare Effectiveness Data and Information Set) is one tool we use to measure many aspects of performance. This document details some of the key features of Statin Therapy for Patients with Cardiovascular Disease (SPC).

What is the measure?
The measure looks at the percentage of males age 21-75 and females age 40-75 during the measurement year who were identified as having clinical atherosclerotic cardiovascular disease (denominator) and who were dispensed at least one high or moderate-intensity statin medication during the measurement year (numerator).

Description
The percentage of males age 21-75 and females age 40-75 during the current measurement year who have been identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria:

- Received statin therapy — members who were dispensed at least one high or moderate-intensity statin medication during the measurement year.

Eligible Members
Members are identified two ways for this measure:

- **Event**: Myocardial infarction (acute and non-acute inpatient stay)
  - Coronary artery bypass graft, percutaneous coronary intervention or other revascularization (any setting)

- **Diagnosis**: Ischemic Vascular Disease (IVD)
  The member needs to meet at least one of the following criteria during both the measurement year and the prior year:
  - At least one outpatient visit with an IVD diagnosis
  - At least one acute inpatient encounter with an IVD diagnosis

(continued next page)
HEDIS Measure: Statin Use in Patients with Cardiovascular Disease (SPC) (continued)

Exclusions

- Pregnancy during the measurement year or the prior year
- In vitro fertilization in the measurement year or the prior year
- Dispensed at least one prescription for clomiphene during measurement year or prior year
- End stage renal disease during the measurement year or the prior year
- Cirrhosis during the measurement year or the prior year
- Myalgia, myositis or rhabdomyolysis during the measurement year, identified through:
  - G72.0 Drug-induced myopathy
  - G72.1 Myopathy due to other toxic agents
  - G72.9 Myopathy, unspecified
  - M62.82 Rhabdomyolysis
  - M79.1 Myalgia

Note: In late 2013, the American College of Cardiology and the American Heart Association published the Guideline on the Treatment to Reduce Atherosclerotic Cardiovascular Risk in Adults to address reducing cardiovascular disease. Specific to this HEDIS measure population, the guideline focuses on statin intensity, with evidence supporting use of high-intensity statin to reduce ASCVD event over moderate-intensity statin. Recognizing statin-associated side effects may preclude a member from receiving a high-intensity statin, the guidelines recommend members receive a moderate-intensity statin.

High and Moderate–Intensity Statin Medications*

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription</th>
</tr>
</thead>
<tbody>
<tr>
<td>High–intensity statin therapy</td>
<td></td>
</tr>
<tr>
<td>atorvastatin 40-80 mg (Tier 6)</td>
<td>simvastatin 80 mg (Tier 6)</td>
</tr>
<tr>
<td>rosvastatin 20-40 mg (Tier 6)</td>
<td>amlodipine and atorvastatin 40-80 mg (Tier 6)</td>
</tr>
<tr>
<td>ezetimibe and atorvastatin 40-80 mg (non-formulary)</td>
<td>ezetimibe and simvastatin 80 mg (non-formulary)</td>
</tr>
<tr>
<td>atorvastatin 10-20 mg (Tier 6)</td>
<td>simvastatin 20-40 mg (Tier 6)</td>
</tr>
<tr>
<td>lovastatin 40 mg (Tier 6)</td>
<td>rosuvastatin 5-10 mg (Tier 6)</td>
</tr>
<tr>
<td>pravastatin 40-80 mg (Tier 6)</td>
<td>amlodipine and atorvastatin 10-20 mg (Tier 6)</td>
</tr>
<tr>
<td>ezetimibe and simvastatin 20-40 mg (Tier 6)</td>
<td>niacin and lovastatin 40 mg (non-formulary)</td>
</tr>
<tr>
<td>sitagliptin – simvastatin 20-40 mg (non-formulary)</td>
<td>fluvastatin XL 80 mg (non-formulary)</td>
</tr>
<tr>
<td>ezetimibe and atorvastatin 10-20 mg (non-formulary)</td>
<td>fluvastatin 40 mg bid (non-formulary)</td>
</tr>
<tr>
<td>niacin and simvastatin 20-40 mg (non-formulary)</td>
<td>pitavastatin 2-4 mg (non-formulary)</td>
</tr>
</tbody>
</table>

*Tier 6 Select Care drugs for generic formulation. $0 copay after any deductible is met.

Content reproduced with permission from HEDIS® 2018, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of this publication, including the full measures and specifications, visit ncqa.org/publications.